Osteochondrodysplasia
RecruitingBMN 333 Versus Vosoritide in Children With Achondroplasia
- Disease:Osteochondrodysplasia
- Substances:Vosoritide
Italy- Participants:0–17 years
- Substances:Vosoritide
- Sponsor:Biomarin Pharmaceutical Inc.
Rare diseases
Investigational molecules
Locations
105 Digital Drive, 94949-8703, United States
BioMarin Pharmaceutical Inc. focuses heavily on conditions affecting linear growth and bone development, including achondroplasia, hypochondroplasia, idiopathic short stature, Turner syndrome, short stature homeobox-containing gene deficiency, and Noonan syndrome. Its research also extends to pediatric growth impairment linked to inadequate response to human growth hormone.
The sponsor’s clinical activity in this area includes children, infants, and adolescents, with a strong emphasis on growth-related outcomes and long-term treatment experience.
Biomarin Pharmaceutical Inc. runs clinical trials in conditions such as Osteochondrodysplasia, Hypochondroplasia, Duchenne muscular dystrophy, Short stature, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Italy
Italy
France
France
France
Italy
France
France
Germany
France
Belgium
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.